Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylene Blue Cation. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.57 |
| ▸ | TERT | O14746 | 1/20 | 0.57 |
| ▸ | APAF1 | O14727 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Blue Cation SCHEMBL12312498 | 1.00 | APP (0.57) | APPTERTAPAF1EGFRPSMB5 | |
| Methylene Blue Cation SCHEMBL12312497 | 1.00 | APP (0.57) | APPTERTAPAF1EGFRPSMB5 | |
| Methylene Blue Cation SCHEMBL29941578 | 1.00 | APP (0.57) | APPTERTAPAF1EGFRPSMB5 | |
| Methylene Blue Cation SCHEMBL128584 | 1.00 | APP (0.57) | APPTERTAPAF1EGFRPSMB5 | |
| Methylene Blue Cation SCHEMBL12312491 | 1.00 | APP (0.57) | APPTERTAPAF1EGFRPSMB5 | |
| Methylene Blue Cation SCHEMBL4565666 | 0.98 | APP (0.55) | APPTERTAPAF1EGFRPSMB5 | |
| Methylene Blue Cation SCHEMBL1926028 | 0.98 | APP (0.55) | APPTERTAPAF1EGFRPSMB5 | |
| Methylene Blue Cation SCHEMBL1351 | 0.98 | APP (0.55) | APPTERTAPAF1EGFRPSMB5 | |
| Methylene Blue Cation SCHEMBL1461350 | 0.98 | APP (0.55) | APPTERTAPAF1EGFRPSMB5 | |
| Methylene Blue Cation SCHEMBL1207285 | 0.98 | APP (0.55) | APPTERTAPAF1EGFRPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 671 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115200-A1 | Treatments Using Methylthioninium Salt, Liquid Mineral Blends, and/or Secondary Physiologically Active Compounds With Physiological Therapies | BEST 365 LABS INC (US) | 2026-04-30 | — | — | US | claimed |
| US-20260083747-A1 | COMPOSITIONS AND METHODS FOR SUPPORTING MITOCHONDRIAL HEALTH | LOPEZ DARREN (US) | 2026-03-26 | — | — | US | claimed |
| US-20260048066-A1 | TREATMENT OF NEURODEGENERATIVE DISORDERS UTILISING METHYLTHIONINIUM (MT)-CONTAINING COMPOUNDS | WISTA LABORATORIES LTD (SG) | 2026-02-19 | — | — | US | claimed |
| EP-4385512-B1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | TAURX THERAPEUTICS MAN LTD (GB) | 2025-12-03 | — | — | EP | claimed |
| EP-4364801-B1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | TAURX THERAPEUTICS MAN LTD (GB) | 2025-11-12 | — | — | EP | claimed |
| US-20250302843-A1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | WISTA LABORATORIES LTD. (SG) | 2025-10-02 | — | — | US | claimed |
| US-20250275980-A1 | METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS | LOPEZ DARREN (US) | 2025-09-04 | — | — | US | claimed |
| EP-4335517-B1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | WISTA LAB LTD (SG) | 2025-08-27 | — | — | EP | claimed |
| US-20250262219-A1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | WISTA LABORATORIES LTD. (SG) | 2025-08-21 | — | — | US | claimed |
| US-20250222005-A1 | METHYLENE BLUE CONTAINING COMPOUNDS FOR THE TREATMENT OF METHAEMOGLOBINAEMIA | Wis Ta Laboratories Ltd. (SG) | 2025-07-10 | — | — | US | claimed |
| EP-2480540-B1 | METHYLTHIONINIUM CHLORIDE PENTAHYDRATE, PREPARATION AND PHARMACEUTICAL USE THEREOF | WISTA LAB LTD (SG) | 2017-11-29 | — | — | EP | claimed |
| EP-2645994-B1 | FORMULATIONS COMPRISING METHYLTHIONINIUM CHLORIDE | WISTA LAB LTD (SG) | 2017-11-01 | — | — | EP | claimed |
| EP-2480541-B1 | CRYSTALLINE METHYLTHIONIUM CHLORIDE (METHYLENE BLUE) HYDRATES | WISTA LAB LTD (SG) | 2015-11-04 | — | — | EP | claimed |
| EP-2046767-B1 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | PROVENCE TECHNOLOGIES (FR) | 2015-04-22 | — | — | EP | claimed |
| EP-2457904-B1 | Methods of synthesis and/or purification of diaminophenothiazinium compounds | WISTA LAB LTD (SG) | 2014-11-19 | — | — | EP | claimed |
| EP-2057136-B1 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS | WISTA LAB LTD (SG) | 2013-05-22 | — | — | EP | claimed |
| EP-1610829-B1 | TISSUE-ADHESIVE FORMULATIONS | TISSUEMED LTD (GB) | 2010-01-20 | — | — | EP | claimed |
| EP-2046767-A2 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | Provence Technologies (FR) | 2009-04-15 | — | — | EP | claimed |
| WO-2009007376-A1 | PHARMACEUTICAL COMPOSITIONS FOR PERORAL ADMINISTRATION OF PHENOTHIAZINE DYESTUFFS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2009-01-15 | — | — | WO | claimed |
| WO-2008006979-A2 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | PROVENCE TECHNOLOGIES (FR) | 2008-01-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222005-A1 | METHYLENE BLUE CONTAINING COMPOUNDS FOR THE TREATMENT OF METHAEMOGLOBINAEMIA | MB, HBB, HMBS | APP 3834/4885TERT 2716/4885APAF1 3138/4885 |
| US-20260048066-A1 | TREATMENT OF NEURODEGENERATIVE DISORDERS UTILISING METHYLTHIONINIUM (MT)-CONTAINING COMPOUNDS | MAPT, PARK7, TARDBP | APP 15/4885TERT 156/4885APAF1 1800/4885 |
| US-20250275980-A1 | METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS | SLC6A12, TPMT, SLC6A5 | APP 3976/4885TERT 674/4885APAF1 4498/4885 |
| US-20260115200-A1 | Treatments Using Methylthioninium Salt, Liquid Mineral Blends, and/or Secondary Physiologically Active Compounds With Physiological Therapies | TPMT, SLC6A6, SLC6A12 | APP 3987/4885TERT 334/4885APAF1 4471/4885 |
| US-20250302843-A1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | MAPT, TPMT, LMTK2 | APP 166/4885TERT 134/4885APAF1 3228/4885 |
| US-20250262219-A1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | ACHE, BCHE, PNMT | APP 111/4885TERT 239/4885APAF1 2211/4885 |
| US-20260083747-A1 | COMPOSITIONS AND METHODS FOR SUPPORTING MITOCHONDRIAL HEALTH | UQCRC2, UQCRC1, MT-ND2 | APP 1633/4885TERT 935/4885APAF1 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.